The purpose of this study is to evaluate the safety and efficacy of AeriSeal treatment in patients with advanced emphysema.
The purpose of this study is to evaluate the safety and efficacy of AeriSeal treatment in patients with advanced homogeneous and heterogeneous emphysema.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
55
AeriSeal System for Lung Volume Reduction
Otto Wagner Spital Wien Interne Lungenabteilung
Vienna, Austria
Service de Pneumologie, Hôpital Pasteur, Centre Hospitalier Universitaire de Nice
Nice, France
Chefarzt Klinik für Pneumologie
Bad Berka, Germany
Thoraxklinik Heidelberg
Heidelberg, Germany
Change from baseline in respiratory volume/total lung capacity (RV/TLC) ratio
Time frame: 12 Weeks following final treatment
Change from baseline in RV/TLC ratio
Time frame: 24 and 48 weeks following treatment
Change from baseline in forced expiratory volume in 1 second (FEV1) (post bronchodilator)
Time frame: 12, 24, 48 weeks following treatment
Change from baseline in MRC dyspnea score
Time frame: 12, 24, 48 weeks following treatment
Change from baseline in 6 minute walk test (MWT)
Time frame: 12, 24, 48 weeks following treatment
Change from baseline in disease-specific health related quality of life assessment (SGRQ)
Time frame: 12, 24, 48 weeks following treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Lungenklinik Hemer
Hemer, Germany
Medizinische Klinik und Poliklinik Klinikum Großhadern
München, Germany
Soroka Medical Center
Beersheba, Israel
Rabin Medical Center, Beilinson Hospital
Petah Tikva, Israel